State of Wisconsin Investment Board Invests $104,000 in Cascadian Therapeutics, Inc. (CASC)

State of Wisconsin Investment Board bought a new stake in Cascadian Therapeutics, Inc. (NASDAQ:CASC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 28,000 shares of the biopharmaceutical company’s stock, valued at approximately $104,000. State of Wisconsin Investment Board owned approximately 0.06% of Cascadian Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlueCrest Capital Management Ltd acquired a new position in shares of Cascadian Therapeutics in the 1st quarter valued at approximately $122,000. Citadel Advisors LLC acquired a new position in shares of Cascadian Therapeutics in the 1st quarter valued at approximately $142,000. Rhumbline Advisers acquired a new position in shares of Cascadian Therapeutics in the 2nd quarter valued at approximately $143,000. Bank of America Corp DE raised its position in shares of Cascadian Therapeutics by 2,316.5% in the 1st quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 35,975 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its position in shares of Cascadian Therapeutics by 8.3% in the 2nd quarter. Perkins Capital Management Inc. now owns 52,129 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 4,000 shares in the last quarter. 82.55% of the stock is currently owned by institutional investors.

Shares of Cascadian Therapeutics, Inc. (CASC) opened at 3.82 on Friday. Cascadian Therapeutics, Inc. has a one year low of $3.18 and a one year high of $10.98. The stock has a 50 day moving average price of $3.72 and a 200-day moving average price of $3.93. The company’s market capitalization is $193.11 million.

Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.06. During the same period in the prior year, the company posted ($1.57) earnings per share. Equities research analysts predict that Cascadian Therapeutics, Inc. will post $5.02 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on CASC shares. Barclays PLC started coverage on Cascadian Therapeutics in a research report on Wednesday, September 6th. They issued an “underweight” rating and a $4.00 target price on the stock. ValuEngine lowered Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Cowen and Company reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research report on Wednesday, August 9th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $4.00 target price on shares of Cascadian Therapeutics in a research report on Thursday, August 31st. Finally, Zacks Investment Research raised Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Cascadian Therapeutics has an average rating of “Hold” and an average target price of $5.63.

ILLEGAL ACTIVITY NOTICE: “State of Wisconsin Investment Board Invests $104,000 in Cascadian Therapeutics, Inc. (CASC)” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://sportsperspectives.com/2017/09/17/state-of-wisconsin-investment-board-invests-104000-in-cascadian-therapeutics-inc-casc.html.

Cascadian Therapeutics Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Want to see what other hedge funds are holding CASC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cascadian Therapeutics, Inc. (NASDAQ:CASC).

Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply